LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and suppresses the integrin-induced tyrosine phosphorylation of paxillin.
Focal adhesion (FA) consists of multiple cellular proteins including paxillin and serves as a center for adhesion-mediated signaling. The assembly and disassembly of FAs is regulated by locally produced intracellular signals, and tyrosine phosphorylation of paxillin has been implicated in this process. A Lin-11 Isl-1 Mec-3 (LIM) domain-containing adaptor protein, leupaxin, a member of the paxillin family, is expressed in leukocytes as well as in certain cancer cells, and shares overall structural characteristics with paxillin. However, it remains unknown whether leupaxin and paxillin cooperate with or antagonize each other in integrin signaling. Here we show that leupaxin potently represses the tyrosine phosphorylation of paxillin. When expressed in mouse thymoma BW5147 cells bound to ICAM-1, leupaxin accumulated in FA-like patches in the cell periphery. When expressed in NIH3T3 and HEK293T cells, leupaxin localized to FAs upon cell adhesion to fibronectin and strongly suppressed the integrin-induced tyrosine phosphorylation of paxillin. In integrin-stimulated HEK293T cells, leupaxin's LIM3 domain appeared essential for selective FA localization and the suppression of paxillin tyrosine phosphorylation. Leupaxin's LD3 motif, which is critical for stable association with FAK, was dispensable for leupaxin's suppressive ability. In addition, leupaxin reduced the spreading of NIH3T3 cells on fibronectin, which required both the LD3 motif and LIM3 domain. When expressed in human leukocytic K562 cells, leupaxin significantly suppressed integrin alpha5beta1-mediated cell adhesion to fibronectin and the tyrosine phosphorylation of paxillin. These findings indicate that leupaxin functions as a paxillin counterpart that potently suppresses the tyrosine phosphorylation of paxillin during integrin signaling.
Tanaka
Toshiyuki
T
Laboratory of Immunodynamics, Department of Microbiology and Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan. tanaka@huhs.ac.jp
Moriwaki
Kazumasa
K
Murata
Shinsuke
S
Miyasaka
Masayuki
M
D000818:Animals; D015815:Cell Adhesion Molecules / Q000502:physiology*; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000502:physiology; D022001:Focal Adhesions; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D020014:K562 Cells; D051379:Mice; D041681:NIH 3T3 Cells; D051419:Paxillin / Q000378:metabolism*; D010750:Phosphoproteins / Q000502:physiology*; D010766:Phosphorylation; D014157:Transcription Factors; D014443:Tyrosine / Q000378:metabolism*
D015815:Cell Adhesion Molecules; D016023:Integrins; C112251:LPXN protein, human; C504469:Lpxn protein, mouse; D051419:Paxillin; D010750:Phosphoproteins; D014157:Transcription Factors; D014443:Tyrosine; D051416:Focal Adhesion Protein-Tyrosine Kinases